Canaccord Genuity Reiterates Buy on Avanir (AVNR) as Drug Sales Ramp

November 28, 2012 2:23 PM EST Send to a Friend
Get Alerts AVNR Hot Sheet
Price: $5.32 --0%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 1 | New: 1
Trade AVNR Now!
Join SI Premium – FREE
Canaccord Genuity maintained a Buy on Avanir Pharmaceuticals (NASDAQ: AVNR) with a price target of $6.00 after the company reported drug sales that beat estimates. Nuedexta gross sales came in a $15.4 million, beating consensus views of $14.8 million.

Commenting on the developments, analysts Ritu Baral said, "Recent sales trends continue to appear steady, and we foresee continued sales ramp in 2013."

Canaccord Genuity's $6 target on Avanir Pharmaceuticals (NASDAQ: AVNR) is based on a sum-of- the-parts analysis.

For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.

Shares of Avanir Pharmaceuticals closed at $2.66 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Canaccord Genuity

Add Your Comment